Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (21-30 of 208) with videos related to

Pageof 21
Sort By:
Journal of Mass Spectrometry : JMS|August 9, 2007
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation studyM Wade Calcutt, Wooin Lee, Igor Puzanov, et al.
Frontiers in Immunology|March 11, 2026
Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical managementBianca Arianna Facchini, Benjamin Switzer, Marc S Ernstoff, et al.
American Journal of Cancer Research|November 12, 2021
Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapyFengzhi Li, Christos Fountzilas, Igor Puzanov, et al.
Current Oncology Reports|May 10, 2020
COVID-19 and Cancer: a Comprehensive ReviewRohit Gosain, Yara Abdou, Abhay Singh, et al.
Oncotargets and Therapy|March 4, 2017
<i>BRAF</i><sup>V600</sup> mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening studyAllen L Cohn, Bann-Mo Day, Sarang Abhyankar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 23, 2024
Evaluation of safety outcomes between nivolumab regimens with differing dosing patternsJoseph Elijah, Igor Puzanov, Benjamin Cresanti, et al.
Communications Medicine|June 13, 2024
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancersBadri Karthikeyan, Sunitha Shyam Sunder, Igor Puzanov, et al.
Oncoimmunology|December 22, 2016
Responses to immune checkpoint inhibitors in nonagenariansRomany A N Johnpulle, Robert M Conry, Jeffrey A Sosman, et al.
Essays in Biochemistry|July 22, 2022
Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemnessXiaozhuo Liu, Wen Jess Li, Igor Puzanov, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumoursMasaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, et al.
Pageof 21

Showing results (21-30 of 208) with videos related to

Sort By:
Pageof 21
Journal of Mass Spectrometry : JMS|August 9, 2007
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation studyM Wade Calcutt, Wooin Lee, Igor Puzanov, et al.
Frontiers in Immunology|March 11, 2026
Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical managementBianca Arianna Facchini, Benjamin Switzer, Marc S Ernstoff, et al.
American Journal of Cancer Research|November 12, 2021
Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapyFengzhi Li, Christos Fountzilas, Igor Puzanov, et al.
Current Oncology Reports|May 10, 2020
COVID-19 and Cancer: a Comprehensive ReviewRohit Gosain, Yara Abdou, Abhay Singh, et al.
Oncotargets and Therapy|March 4, 2017
<i>BRAF</i><sup>V600</sup> mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening studyAllen L Cohn, Bann-Mo Day, Sarang Abhyankar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 23, 2024
Evaluation of safety outcomes between nivolumab regimens with differing dosing patternsJoseph Elijah, Igor Puzanov, Benjamin Cresanti, et al.
Communications Medicine|June 13, 2024
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancersBadri Karthikeyan, Sunitha Shyam Sunder, Igor Puzanov, et al.
Oncoimmunology|December 22, 2016
Responses to immune checkpoint inhibitors in nonagenariansRomany A N Johnpulle, Robert M Conry, Jeffrey A Sosman, et al.
Essays in Biochemistry|July 22, 2022
Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemnessXiaozhuo Liu, Wen Jess Li, Igor Puzanov, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumoursMasaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, et al.
Pageof 21